|Dr. Sean Emerson George||Co-Founder, Pres, CEO & Director||451.35k||625.9k||1974|
|Mr. Kenneth D. Knight||Chief Operating Officer||428.5k||N/A||1961|
|Mr. Thomas R. Brida||Gen. Counsel, Chief Compliance Officer & Sec.||348.75k||N/A||1971|
|Mr. Lee Bendekgey||Chief Policy Officer||383.64k||2.07M||1958|
|Mr. Alex Furman||Co-Founder, Culture Tsar & Head of People Analytics||N/A||N/A||N/A|
|Ms. Michele Cargill Ph.D.||Co-Founder, Key Projects & Advisor to the CEO||N/A||N/A||N/A|
|Mr. Robert F. Werner||Chief Accounting Officer & Principal Accounting Officer||N/A||N/A||1973|
|Mr. Layton Wedgeworth||Chief Technology Officer||N/A||N/A||N/A|
|Ms. Laura D'Angelo||Head of Investor Relations||N/A||N/A||N/A|
|Ms. Desarie French||Chief Talent Officer||N/A||N/A||N/A|
Invitae Corporation, a medical genetics company, integrates genetic information into healthcare decision-making by clinicians and patients in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and rare diseases. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was founded in 2010 and is headquartered in San Francisco, California.
Invitae Corporation’s ISS governance QualityScore as of 1 June 2021 is 5. The pillar scores are Audit: 5; Board: 2; Shareholder rights: 7; Compensation: 8.